- Home
- AMRN vs ALDX Comparison
AMRN vs ALDX Comparison
Compare AMRN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- ALDX
- Stock Information
- Founded
- AMRN 1989
- ALDX 2004
- Country
- AMRN Ireland
- ALDX United States
- Employees
- AMRN N/A
- ALDX N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- ALDX Health Care
- Exchange
- AMRN Nasdaq
- ALDX Nasdaq
- Market Cap
- AMRN 339.8M
- ALDX 296.0M
- IPO Year
- AMRN 1993
- ALDX 2014
- Fundamental
- Price
- AMRN $15.93
- ALDX $5.22
- Analyst Decision
- AMRN Strong Sell
- ALDX Strong Buy
- Analyst Count
- AMRN 1
- ALDX 2
- Target Price
- AMRN $12.00
- ALDX $9.50
- AVG Volume (30 Days)
- AMRN 109.8K
- ALDX 670.9K
- Earning Date
- AMRN 10-29-2025
- ALDX 11-05-2025
- Dividend Yield
- AMRN N/A
- ALDX N/A
- EPS Growth
- AMRN N/A
- ALDX N/A
- EPS
- AMRN N/A
- ALDX N/A
- Revenue
- AMRN $226,733,000.00
- ALDX N/A
- Revenue This Year
- AMRN N/A
- ALDX N/A
- Revenue Next Year
- AMRN N/A
- ALDX $63.48
- P/E Ratio
- AMRN N/A
- ALDX N/A
- Revenue Growth
- AMRN N/A
- ALDX N/A
- 52 Week Low
- AMRN $7.08
- ALDX $1.14
- 52 Week High
- AMRN $20.90
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- AMRN 41.03
- ALDX 54.47
- Support Level
- AMRN $15.74
- ALDX $4.70
- Resistance Level
- AMRN $17.25
- ALDX $5.35
- Average True Range (ATR)
- AMRN 0.71
- ALDX 0.27
- MACD
- AMRN 0.04
- ALDX 0.02
- Stochastic Oscillator
- AMRN 40.64
- ALDX 86.67
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.